You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK):“注射用福沙匹坦雙葡甲胺”獲藥品註冊批件
格隆匯 10-30 19:08

格隆匯10月30日丨中國生物製藥(01177.HK)發佈公告,由公司附屬公司正大天晴藥業集團股份有限公司開發的預防化療引起的噁心嘔吐藥物“注射用福沙匹坦雙葡甲胺”(商品名稱“善啟”),已獲國家藥品監督管理局頒發藥品註冊批件。該產品註冊分類為原化學藥品第3.1類,獲批的適應症為:與其他止吐藥物聯合給藥,適用於成年患者預防高度致吐化療藥物初次和重複治療過程中出現的急性和遲發性噁心和嘔吐。

根據披露,福沙匹坦雙葡甲胺是一種神經激肽-1(NK-1)受體拮抗劑,是阿瑞匹坦的前藥,具有全新的作用機制、療效肯定、安全性高、臨牀適用廣泛等特點。作為臨牀急需藥,福沙匹坦雙葡甲胺被列入中國《第一批鼓勵仿製藥品目錄》。

目前國內臨牀上化療止吐的藥物主要為5-HT3受體拮抗劑,其止吐效果明顯,但因嘔吐劇烈程度不同而難以完全有效控制。福沙匹坦雙葡甲的出現使化療相關噁心嘔吐的治療從所謂的“5-HT3受體拮抗劑時代”進入一個全新時代,擁有巨大的市場空間。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account